# A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.

> **NCT00503425** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 215 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Rituximab [MabThera/Rituxan]

## Key facts

- **NCT ID:** NCT00503425
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06-30
- **Primary completion:** 2013-05-26
- **Final completion:** 2013-05-26
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2017-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00503425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00503425, "A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00503425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*